Literature DB >> 12753862

The components of excess mortality after hip fracture.

J A Kanis1, A Oden, O Johnell, C De Laet, B Jonsson, A K Oglesby.   

Abstract

A high excess mortality is well described after hip fracture. Deaths are in part related to comorbidity and in part due directly or indirectly to the hip fracture event itself (causally related deaths). The aim of this study was to examine the quantum and pattern of mortality following hip fracture. We studied 160,000 hip fractures in men and women aged 50 years or more, in 28.8 million person-years from the patient register of Sweden, using Poisson models applied to hip fracture patients and the general population. At all ages the risk of death was markedly increased compared with population values immediately after the event. Mortality subsequently decreased over a period of 6 months, but thereafter remained higher than that of the general population. The latter function was assumed to account for deaths related to comorbidity and the residuum assumed to be due to the hip fracture. Causally related deaths comprised 17-32% of all deaths associated with hip fracture (depending on age) and accounted for more than 1.5% of all deaths in the population aged 50 years or more. Hip fracture was a more common cause for mortality than pancreatic or stomach cancer. Thus, interventions that decreased hip fracture rate by, say, 50% would avoid 0.75% or more of all deaths.

Entities:  

Mesh:

Year:  2003        PMID: 12753862     DOI: 10.1016/s8756-3282(03)00061-9

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  183 in total

1.  Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective.

Authors:  F Borgström; O Ström; M Kleman; E McCloskey; H Johansson; A Odén; J A Kanis
Journal:  Osteoporos Int       Date:  2010-06-08       Impact factor: 4.507

2.  Bone health in healthy Indian population aged 50 years and above.

Authors:  R K Marwaha; N Tandon; M K Garg; R Kanwar; A Narang; A Sastry; A Saberwal; K Bhadra; A Mithal
Journal:  Osteoporos Int       Date:  2011-01-27       Impact factor: 4.507

3.  Development of physical performance after acute hip fracture: an observational study in a regular clinical geriatric setting.

Authors:  Davidpremkumar Chandrasekaran; Asa Andersson; Maria Hindenborg; Rolf Norlin; Gunnar Akner
Journal:  Geriatr Orthop Surg Rehabil       Date:  2014-09

4.  Hip fracture and increased short-term but not long-term mortality in healthy older women.

Authors:  Erin S LeBlanc; Teresa A Hillier; Kathryn L Pedula; Joanne H Rizzo; Peggy M Cawthon; Howard A Fink; Jane A Cauley; Douglas C Bauer; Dennis M Black; Steven R Cummings; Warren S Browner
Journal:  Arch Intern Med       Date:  2011-09-26

5.  Prevalence of osteoporosis in men aged 65-75 in a primary care setting. A practice audit after application of the Canadian 2010 guidelines for osteoporosis screening.

Authors:  Robert Ferrari
Journal:  Clin Rheumatol       Date:  2014-04-30       Impact factor: 2.980

Review 6.  The pathogenesis, treatment and prevention of osteoporosis in men.

Authors:  Leif Mosekilde; Peter Vestergaard; Lars Rejnmark
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

7.  Mortality after osteoporotic fractures.

Authors:  O Johnell; J A Kanis; A Odén; I Sernbo; I Redlund-Johnell; C Petterson; C De Laet; B Jönsson
Journal:  Osteoporos Int       Date:  2003-10-30       Impact factor: 4.507

8.  Excess mortality after hospitalisation for vertebral fracture.

Authors:  John A Kanis; Anders Oden; Olof Johnell; Chris De Laet; Bengt Jonsson
Journal:  Osteoporos Int       Date:  2003-11-04       Impact factor: 4.507

9.  Quality of life, morbidity, and mortality after low trauma hip fracture in men.

Authors:  I Pande; D L Scott; T W O'Neill; C Pritchard; A D Woolf; M J Davis
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103

10.  Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.

Authors:  O Ström; B Jönsson; J A Kanis
Journal:  Osteoporos Int       Date:  2012-12-07       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.